Viacure GmbH

Viacure is a Munich-based bioscience company dedicated to the development of regenerative therapies for the causal treatment of type 2 diabetes. As a spin-off from Helmholtz Munich, Viacure is based on a groundbreaking scientific discovery: the inceptor - a receptor that inhibits insulin action in beta cells. By specifically blocking this receptor with therapeutic antibodies, the regeneration and function of insulin-producing cells is restored. Our approach goes beyond the mere treatment of symptoms. We are tackling the cause of type 2 diabetes - with the potential to sustainably improve the quality of life for millions of sufferers and at the same time reduce the economic costs of this chronic disease. The founding team combines scientific excellence and entrepreneurial vision: Scientific Director: Prof. Dr. Heiko Lickert Dr. Heiko Lickert is director of the Institute for Diabetes and Cell Regeneration Research at Helmholtz Munich and is a leading expert in cell regeneration. Managing Director: Dr. Nikolas Uez Dr. Nikolas Uez is extensively active as an entrepreneur after his research time on developmental genetics at Helmholtz Munich. Head of the Technology Department: Dr. Wolfgang Burger Dr. Wolfgang Burger Burger is the founder and manager of a Contract Development and Manufacturing Organization (CDMO) and has 30 years of pharmaceutical experience in development and manufacturing. Scientific Project Manager: Dr. Carolina Ballester-Lopez Dr. Carolina Ballester-López brings over eleven years of experience in cell biology and immunology, including expertise in antibody development at Roche Pharma Viacure stands for scientific precision, therapeutic innovation and social relevance. We are working to redefine the future of diabetes treatment - regenerative, sustainable and evidence-based.